Smith & Nephew puts up $660m for Osiris Therapeutics

Smith & Nephew puts up $660m for Osiris Therapeutics

Source: 
Mass Device
snippet: 

Smith & Nephew (NYSE:SNN) said today that it agreed to put $660 million on the table to acquire Osiris Therapeutics (NSDQ:OSIR) and its regenerative medicine portfolio.